Tumor flare with T-cell-engaging bispecific antibodies.

Autor: Carlo-Stella C; Department of Biochemical Sciences, Humanitas University, Rozzano, Milano, Italy.; Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy., Dickinson MJ; PeterMacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Victoria, Australia., Iacoboni G; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Campus, Barcelona, Spain.; Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain., Carpio C; Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Campus, Barcelona, Spain., Dimier N; Roche Products Ltd, Welwyn Garden City, United Kingdom., Weisser M; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany., Kwan A; Product Development Safety, Genentech, Inc., South San Francisco, CA, USA., Ferlini C; Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2024 Oct; Vol. 65 (10), pp. 1524-1527. Date of Electronic Publication: 2024 Jun 05.
DOI: 10.1080/10428194.2024.2361100
Databáze: MEDLINE